Cardiology

Your Article Summary

See Latest Articles

Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): A multicentre, randomised, open-label trial
The Lancet - Early Online Publication, 06/09/09

Home PD et al. – Addition of rosiglitazone to glucose-lowering therapy in pts with type 2 diabetes is confirmed to increase risk of heart failure and of some fractures, mainly in women. Despite inconclusive data are about any possible effect on myocardial infarction, rosiglitazone does not increase risk of overall cardiovascular morbidity or mortality compared with standard glucose-lowering drugs.

• Study of cardiovascular outcomes after addition of rosiglitazone to either metformin or sulfonylurea vs combination over 5—7 yr follow-up
• Assessment of comparative safety
• Multicentre, open-label trial of 4447 pts with type 2 diabetes on metformin or sulfonylurea monotherapy with mean hemoglobin A1c (HbA1c) of 7.9%
• Randomization to addition of rosiglitazone (n=2220) or combination of metformin and sulfonylurea (active control group, n=2227)
• Primary endpoint: cardiovascular hospitalization or cardiovascular death

• 321 pts in rosiglitazone group and 323 in active control group experienced primary outcome during mean 5.5-yr follow-up, meeting criterion of non-inferiority
• HR was 0.84 for cardiovascular death, 1.14 for myocardial infarction, and 0.72 for stroke
• Heart failure causing admission to hospital or death in 61 people in rosiglitazone group and 29 in active control group
• Upper and distal lower limb fracture rates increased mainly in women assigned to rosiglitazone
• Mean HbA1c lower in rosiglitazone vs control group at 5 yrs

Related Articles

See all related articles

Rosiglitazone Decreases C-Reactive Protein to a Greater Extent Relative to Glyburide and Metformin over Four-Years in Spite of Greater Weight Gain: Observations from ADOPT (A Diabetes Outcome Progression Trial)
Diabetes Care, 10/14/09    Relevance Score: 88%

Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: Results of the fatty liver improvement by rosiglitazone therapy (FLIRT 2) extension trial
Hepatology, 11/02/09    Relevance Score: 87%

Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus
Metabolism-Clinical and Experimental, 10/26/09    Relevance Score: 87%

Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics of Rosiglitazone
Cardiovascular Drug Reviews, 11/17/09    Relevance Score: 85%

Stretch Reduces Nephrin Expression via an Angiotensin II-AT1-dependent Mechanism in Human Podocytes: Effect of Rosiglitazone
American Journal of Physiology: Renal Physiology, 11/17/09    Relevance Score: 85%

Today in Coronary Artery Disease...keeping you current

Receive free subspecialty "5-minute updates" via email

The New Method of Time-Lag Ligation for Portosystemic Shunt Using Coronary Artery Bypass Graft Occluder for Adult Living Donor Liver Transplantation
Transplantation Proceedings, 12/16/09

Interaction Between Cigarette Smoking and High-Sensitivity C-Reactive Protein in the Development of Coronary Vasospasm in Patients Without Hemodynamically Significant Coronary Artery Disease
The American Journal of the Medical Sciences, 12/16/09

Usefulness of Fragmented QRS on a 12-Lead Electrocardiogram in Acute Coronary Syndrome for Predicting Mortality
The American Journal of Cardiology, 12/16/09

 See all of Coronary Artery Disease